BNIP3P17

Across TCGA pan-cancer cohorts, BNIP3P17 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of BNIP3P17’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where BNIP3P17 RNA is repressed in tumor relative to normal tissue. In most cancer types BNIP3P17 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, BLCA, and STAD are the cancer types where BNIP3P17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BNIP3P17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−2.005	<.001	11	view →
BLCA	Male	III,IV	+2.121	<.001	10	view →
STAD	All	II,III,IV	+0.771	<.001	7	view →
BRCA	All	III,IV	+1.009	<.001	6	view →
LUAD	Male	All	+0.728	<.001	6	view →
LUSC	All	II,III,IV	+0.426	.010	5	view →
KICH	All	II,III,IV	−0.406	<.001	5	view →
LIHC	All	All	+0.328	<.001	4	view →
READ	All	II,III,IV	−0.657	.024	1	view →
CHOL	All	All	+0.595	.006	1	view →
LUSC	Female	III,IV	−0.540	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 10 lineages.

BNIP3P17–THCA

Open the THCA breakdown →